Antibiotic Management for Pneumonia

Rationale for Antibiotic Addition

The Infectious Diseases Society of America recommends adding a beta-lactam antibiotic, such as ceftriaxone 1-2 g IV daily, plus a macrolide, such as azithromycin 500 mg IV/PO daily, to the current regimen for patients with pneumonia, as clindamycin and Bactrim do not provide adequate coverage for the most common pneumonia pathogens, particularly Streptococcus pneumoniae and atypical organisms 1, 2
Clindamycin provides coverage for methicillin-susceptible Staphylococcus aureus and some anaerobes, but has variable activity against Streptococcus pneumoniae and no coverage for atypical pathogens like Mycoplasma pneumoniae or Chlamydophila pneumoniae 1, 3
Trimethoprim-sulfamethoxazole has activity against some gram-positive and gram-negative organisms, but is not recommended as first-line therapy for pneumococcal pneumonia and lacks coverage for atypical pathogens 2, 3

For hospitalized patients not requiring ICU admission, the preferred first-line therapy is a beta-lactam plus macrolide combination, such as ceftriaxone 1-2 g IV daily plus azithromycin 500 mg IV/PO daily, which provides comprehensive coverage for S. pneumoniae, H. influenzae, atypical pathogens, and most other common CAP organisms 1, 2
An alternative option is respiratory fluoroquinolone monotherapy, such as levofloxacin 750 mg IV/PO daily or moxifloxacin 400 mg IV/PO daily, which provides broad-spectrum coverage including atypicals 1, 2

The Infectious Diseases Society of America recommends continuing clindamycin and Bactrim for the wound infection while adding pneumonia-specific coverage, as these agents are appropriate for skin and soft tissue infections 4, 5
If the wound infection is due to MRSA and clindamycin-susceptible, continuing clindamycin is reasonable 5

If MRSA pneumonia is suspected, the Infectious Diseases Society of America recommends adding vancomycin 15-20 mg/kg IV q8-12h or linezolid 600 mg IV/PO q12h to the beta-lactam/macrolide regimen 2, 5
The existing clindamycin may have some activity against community-acquired MRSA if the strain is susceptible, but vancomycin or linezolid are preferred for severe pneumonia 2, 5

The Infectious Diseases Society of America recommends obtaining blood cultures and sputum cultures before adding antibiotics, if feasible, to guide subsequent pathogen-directed therapy 1, 2

The American Thoracic Society recommends amoxicillin 500 mg-1 g PO q8h for 5-7 days for low severity CAP outpatient treatment 6
For moderate severity CAP, initial IV therapy with amoxicillin/clavulanate 1.2 g IV q8h → 1-2 g PO q12h is recommended, with a duration of 5-7 days if afebrile for 48 hours and clinically stable 6, 7
The Infectious Diseases Society of America suggests doxycycline 100 mg PO q12h for 7-14 days for suspected atypical pathogens (Mycoplasma, Chlamydophila) 7, 8

The American Academy of Dermatology recommends amoxicillin/clavulanate 875/125 mg PO q12h for 7-10 days for uncomplicated skin and soft tissue infections 7
For MRSA coverage, linezolid 600 mg PO q12h for 10-14 days is recommended 7

For Streptococcus pneumoniae, penicillin-susceptible strains can be treated with amoxicillin 1 g PO q8h for 5-7 days, while penicillin-resistant strains require high-dose amoxicillin/clavulanate 2000/125 mg PO q12h for 7-10 days 7, 8
For Staphylococcus aureus, methicillin-susceptible strains can be treated with dicloxacillin 500 mg PO q6h or cephalexin 500 mg PO q6h for 7-14 days, while methicillin-resistant strains require linezolid 600 mg PO q12h for 10-14 days 7, 8

The duration of therapy for most uncomplicated pneumonia is 5-7 days if the patient becomes afebrile within 48-72 hours and shows clinical improvement 6
Empiric treatment with levofloxacin and moxifloxacin for pneumonia may delay diagnosis of tuberculosis in endemic areas and increase risk of resistance 6, 7
Switching from IV to oral therapy should be considered when the patient is clinically stable (temperature ≤37.8°C, heart rate ≤100/min, respiratory rate ≤24/min, SBP ≥90 mmHg, O2 saturation ≥90%) 6, 9
Treatment failure should prompt consideration of resistant pathogens, inadequate dosing, or non-infectious causes if no clinical improvement after 72 hours of appropriate therapy 10, 9